Navigation Links
NeoStem Appoints Deloitte & Touche as New Independent Registered Public Accounting Firm

NEW YORK, March 16 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. ( NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today the appointment of Deloitte & Touche LLP ("Deloitte & Touche") as the Company's independent registered public accountant for fiscal year 2010.

The decision to change independent registered public accounting firms was recommended and approved by NeoStem's Audit Committee of the board of directors on March 11. NeoStem's engagement with current auditor Holtz Rubenstein Reminick LLP ("HRR") will end following completion of the 2009 audit of the Company's financial statements and filing of the Form 10-K. HRR's audit of NeoStem's 2007 and 2008 financial statements did not contain any adverse opinions or disclaimer of opinion, and there have been no disagreements between the Company and HRR on any matter regarding accounting principles or practices, financial statement disclosure or auditing scope or procedure during fiscal 2007, fiscal 2008 and the subsequent interim period through March 11, 2010.

"Over the past year, NeoStem has evolved into a sophisticated multinational operation with multiple businesses in the U.S. and China and has more complex financial and accounting needs, which we believe are best serviced by a Big Four accounting firm, such as Deloitte & Touche," said Robin Smith, M.D., NeoStem's CEO and Chairman of the board of directors. "We thank HRR for their adept service in recent years and look forward to working with Deloitte & Touche as the Company continues to grow and increase shareholder value."

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to continued growth of the Company, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on as well as periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    For more information, please contact:

    NeoStem, Inc.
     Robin Smith, CEO
     Phone: +1-212-584-4174

    CCG Investor Relations, Inc.
     Lei Huang, Account Manager
     Phone: +1-646-833-3417

     Crocker Coulson, President
     Phone: +1-646-213-1915

SOURCE NeoStem, Inc.

Back to top



SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem Announces Presentation Time Change at Roth Capital Partners 22nd Annual OC Growth Stock Conference
2. NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant
3. NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock
4. Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network
5. NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company
6. United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com
7. NeoStem, Inc. Awarded NIH Research and Research Infrastructure Grand Opportunities Grant
8. NeoStem CEO to Participate in 2009 World Stem Cell Summit on September 23rd
9. NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%
10. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
11. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... RALEIGH, N.C. , Nov. 24, 2015  Clintrax Global, Inc., ... Raleigh, North Carolina , today announced that the company has ... earnings represented a 391% quarter on quarter growth posted for Q3 ... Kingdom and Mexico , with the ... place in December 2015. --> United Kingdom ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
Breaking Biology Technology:
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
Breaking Biology News(10 mins):